ARS Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for ARS Pharmaceuticals, Inc. (SPRY), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are SPRY insiders buying or selling?
In the last 12 months, ARS Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 4 sales ($1.9M) — net selling of $1.9M. Since December 2020, Trabud has recorded 104 Form 4 filings for SPRY: 16 buys ($109.5M) and 88 sells ($121.4M).
Source: SEC EDGAR Form 4
Key Statistics (December 2020 – Jun 13, 2026)
Total Form 4 filings
104
SEC EDGAR
Insider filers
19
Insider buys (16)
$109.5M
Insider sells (88)
$121.4M
Insider sentiment
Net sellingNet insider flow of $11.9M in net selling since December 2020, and $1.9M in net selling over the last 12 months.
Recent SPRY insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 13, 2026 | Eric Karas | Chief Commercial Officer | Sale | 25.0K | $10.00 | $250.0K | SEC ↗ |
| Jun 13, 2026 | Alexander A Fitzpatrick | Chief Legal Officer | Sale | 3.4K | $10.00 | $33.5K | SEC ↗ |
| Nov 14, 2025 | Brian Dorsey | Chief Operating Officer | Sale | 21.8K | $8.71 | $190.0K | SEC ↗ |
| Nov 14, 2025 | Justin Chakma | Chief Business Officer | Sale | 166.4K | $8.87 | $1.5M | SEC ↗ |
| Aug 22, 2025 | Lowenthal Richard E | PRESIDENT AND CEO | Sale | 50.0K | $14.49 | $724.3K | SEC ↗ |
| Aug 22, 2025 | Kathleen D. Scott | Chief Financial Officer | Sale | 12.5K | $15.00 | $187.5K | SEC ↗ |
| Aug 21, 2025 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Sale | 50.0K | $14.08 | $703.8K | SEC ↗ |
| Jul 3, 2025 | Eric Karas | Chief Commercial Officer | Sale | 15.0K | $16.99 | $254.9K | SEC ↗ |
| Jul 1, 2025 | Flynn James E | 10% Owner | Sale | 740.1K | $18.46 | $13.7M | SEC ↗ |
| Jun 20, 2025 | Eric Karas | Chief Commercial Officer | Sale | 15.0K | $16.00 | $240.0K | SEC ↗ |
| May 22, 2025 | Alexander A Fitzpatrick | Chief Legal Officer | Sale | 103.0K | $14.10 | $1.5M | SEC ↗ |
| May 22, 2025 | Brent L Saunders | Director | Sale | 120.0K | $14.25 | $1.7M | SEC ↗ |
| May 22, 2025 | Kathleen D. Scott | Chief Financial Officer | Sale | 50.0K | $14.10 | $705.2K | SEC ↗ |
| Apr 8, 2025 | Laura Shawver | Director | Sale | 50.0K | $12.30 | $615.1K | SEC ↗ |
| Mar 21, 2025 | Eric Karas | Chief Commercial Officer | Sale | 10.0K | $14.00 | $140.0K | SEC ↗ |
| Mar 7, 2025 | Laura Shawver | Director | Sale | 50.0K | $11.21 | $560.4K | SEC ↗ |
| Feb 4, 2025 | Laura Shawver | Director | Sale | 50.0K | $12.31 | $615.6K | SEC ↗ |
| Jan 7, 2025 | Laura Shawver | Director | Sale | 50.0K | $11.10 | $555.1K | SEC ↗ |
| Dec 19, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Sale | 100.0K | $11.67 | $1.2M | SEC ↗ |
| Dec 19, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Sale | 100.0K | $11.67 | $1.2M | SEC ↗ |
| Dec 14, 2024 | Justin Chakma | Chief Business Officer | Sale | 144.6K | $12.23 | $1.8M | SEC ↗ |
| Dec 14, 2024 | Brian Dorsey | Chief Operating Officer | Sale | 40.0K | $12.35 | $493.9K | SEC ↗ |
| Dec 12, 2024 | Justin Chakma | Chief Business Officer | Sale | 50.0K | $13.15 | $657.6K | SEC ↗ |
| Dec 11, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Sale | 100.0K | $13.16 | $1.3M | SEC ↗ |
| Dec 11, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Sale | 100.0K | $13.16 | $1.3M | SEC ↗ |
Showing the 25 most recent of 104 Form 4 filings for ARS Pharmaceuticals, Inc..
Most active SPRY insiders
- Lowenthal Richard E23 filings
- Tanimoto Sarina23 filings
- Laura Shawver12 filings
- Eric Karas7 filings
- Justin Chakma6 filings
Ask anything about SPRY insider activity
Use Trabud's AI agent to query ARS Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me SPRY CEO purchases this year" or compare it against any other ticker.
Open the AI agentSPRY insider trading FAQ
Are ARS Pharmaceuticals, Inc. insiders buying or selling?
In the last 12 months, ARS Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 4 sales ($1.9M) — net selling of $1.9M. Since December 2020, Trabud has recorded 104 Form 4 filings for SPRY: 16 buys ($109.5M) and 88 sells ($121.4M). Over the full record that is net selling of $11.9M.
How many insiders trade SPRY stock?
19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for ARS Pharmaceuticals, Inc.. The most recent filing was accepted on Jun 13, 2026.
Where does Trabud get SPRY insider trading data?
All SPRY insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.